Creating a new antiviral treatment for seasonal and highly-pathogenic influenza viruses
Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses
This study is working on a new oral medication to help treat the flu in adults who aren't in the hospital, aiming to make it safe and effective against different types of flu viruses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia State University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10544324 on NIH RePORTER |
What this research studies
This research focuses on developing a new class of antiviral drugs aimed at treating influenza viruses, which are a major cause of respiratory infections worldwide. The approach involves creating a pyrimidine analog that can be taken orally and is effective against various strains of influenza, including those from humans, birds, and pigs. The goal is to ensure that this new treatment is safe and effective for non-hospitalized adults suffering from seasonal influenza. The research utilizes advanced drug screening techniques to identify effective compounds against these viruses.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are experiencing symptoms of influenza.
Not a fit: Patients who are not experiencing influenza symptoms or those under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective oral treatment option for patients suffering from influenza, potentially reducing the severity and duration of the illness.
How similar studies have performed: Previous research has shown promise in developing antiviral treatments for influenza, indicating that this approach may lead to significant advancements in treatment options.
Where this research is happening
Atlanta, United States
- Georgia State University — Atlanta, United States (Active)
Researchers
- Principal investigator: Plemper, Richard K. — Georgia State University
- Study coordinator: Plemper, Richard K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.